Global Short-acting Insulin Market Growth 2026-2032
The global Short-acting Insulin market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.It is used to control blood Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.This type of insulin starts working within about 15 to 30 minutes after injection,and continues to lower blood sugar for approximately 3 to 6 hours.Its primary function is to manage blood sugar levels by facilitating the uptake of glucose into cells.
United States market for Short-acting Insulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Short-acting Insulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Short-acting Insulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Short-acting Insulin players cover Eli Lilly, Novo Nordisk, Biocon Biologics, Sanofi, Wockhardt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Short-acting Insulin Industry Forecast? looks at past sales and reviews total world Short-acting Insulin sales in 2025, providing a comprehensive analysis by region and market sector of projected Short-acting Insulin sales for 2026 through 2032. With Short-acting Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Short-acting Insulin industry.
This Insight Report provides a comprehensive analysis of the global Short-acting Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Short-acting Insulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting Insulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting Insulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting Insulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.It is used to control blood Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.This type of insulin starts working within about 15 to 30 minutes after injection,and continues to lower blood sugar for approximately 3 to 6 hours.Its primary function is to manage blood sugar levels by facilitating the uptake of glucose into cells.
United States market for Short-acting Insulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Short-acting Insulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Short-acting Insulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Short-acting Insulin players cover Eli Lilly, Novo Nordisk, Biocon Biologics, Sanofi, Wockhardt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Short-acting Insulin Industry Forecast? looks at past sales and reviews total world Short-acting Insulin sales in 2025, providing a comprehensive analysis by region and market sector of projected Short-acting Insulin sales for 2026 through 2032. With Short-acting Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Short-acting Insulin industry.
This Insight Report provides a comprehensive analysis of the global Short-acting Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Short-acting Insulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting Insulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting Insulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting Insulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Regular Insulin
- Biosynthetic Human Insulin
- Recombinant Human Insulin
- Other
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Complications of Diabetes
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Eli Lilly
- Novo Nordisk
- Biocon Biologics
- Sanofi
- Wockhardt
- Bayer
- Pfizer
- BASF
- Abbott Laboratories
- Tonghua Dongbao Pharmaceutical
- Zhuhai United Pharmaceutical
- Sinovac Biotech
- Wanbang Biopharmaceuticals
- HTBT
- What is the 10-year outlook for the global Short-acting Insulin market?
- What factors are driving Short-acting Insulin market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How doShort-acting Insulin market opportunities vary by end market size?
- How does Short-acting Insulin break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Short-acting Insulin Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Short-acting Insulin by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Short-acting Insulin by Country/Region, 2021, 2025 & 2032
2.2 Short-acting Insulin Segment by Type
2.2.1 Regular Insulin
2.2.2 Biosynthetic Human Insulin
2.2.3 Recombinant Human Insulin
2.2.4 Other
2.2.5 Short-acting Insulin Sales by Type
2.2.5.1 Global Short-acting Insulin Sales Market Share by Type (2021-2026)
2.2.5.2 Global Short-acting Insulin Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Short-acting Insulin Sale Price by Type (2021-2026)
2.3 Short-acting Insulin Segment by Application
2.3.1 Type 1 Diabetes
2.3.2 Type 2 Diabetes
2.3.3 Gestational Diabetes
2.3.4 Complications of Diabetes
2.3.5 Other
2.3.6 Short-acting Insulin Sales by Application
2.3.6.1 Global Short-acting Insulin Sale Market Share by Application (2021-2026)
2.3.6.2 Global Short-acting Insulin Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Short-acting Insulin Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Short-acting Insulin Breakdown Data by Company
3.1.1 Global Short-acting Insulin Annual Sales by Company (2021-2026)
3.1.2 Global Short-acting Insulin Sales Market Share by Company (2021-2026)
3.2 Global Short-acting Insulin Annual Revenue by Company (2021-2026)
3.2.1 Global Short-acting Insulin Revenue by Company (2021-2026)
3.2.2 Global Short-acting Insulin Revenue Market Share by Company (2021-2026)
3.3 Global Short-acting Insulin Sale Price by Company
3.4 Key Manufacturers Short-acting Insulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Short-acting Insulin Product Location Distribution
3.4.2 Players Short-acting Insulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SHORT-ACTING INSULIN BY GEOGRAPHIC REGION
4.1 World Historic Short-acting Insulin Market Size by Geographic Region (2021-2026)
4.1.1 Global Short-acting Insulin Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Short-acting Insulin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Short-acting Insulin Market Size by Country/Region (2021-2026)
4.2.1 Global Short-acting Insulin Annual Sales by Country/Region (2021-2026)
4.2.2 Global Short-acting Insulin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Short-acting Insulin Sales Growth
4.4 APAC Short-acting Insulin Sales Growth
4.5 Europe Short-acting Insulin Sales Growth
4.6 Middle East & Africa Short-acting Insulin Sales Growth
5 AMERICAS
5.1 Americas Short-acting Insulin Sales by Country
5.1.1 Americas Short-acting Insulin Sales by Country (2021-2026)
5.1.2 Americas Short-acting Insulin Revenue by Country (2021-2026)
5.2 Americas Short-acting Insulin Sales by Type (2021-2026)
5.3 Americas Short-acting Insulin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Short-acting Insulin Sales by Region
6.1.1 APAC Short-acting Insulin Sales by Region (2021-2026)
6.1.2 APAC Short-acting Insulin Revenue by Region (2021-2026)
6.2 APAC Short-acting Insulin Sales by Type (2021-2026)
6.3 APAC Short-acting Insulin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Short-acting Insulin by Country
7.1.1 Europe Short-acting Insulin Sales by Country (2021-2026)
7.1.2 Europe Short-acting Insulin Revenue by Country (2021-2026)
7.2 Europe Short-acting Insulin Sales by Type (2021-2026)
7.3 Europe Short-acting Insulin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Short-acting Insulin by Country
8.1.1 Middle East & Africa Short-acting Insulin Sales by Country (2021-2026)
8.1.2 Middle East & Africa Short-acting Insulin Revenue by Country (2021-2026)
8.2 Middle East & Africa Short-acting Insulin Sales by Type (2021-2026)
8.3 Middle East & Africa Short-acting Insulin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Short-acting Insulin
10.3 Manufacturing Process Analysis of Short-acting Insulin
10.4 Industry Chain Structure of Short-acting Insulin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Short-acting Insulin Distributors
11.3 Short-acting Insulin Customer
12 WORLD FORECAST REVIEW FOR SHORT-ACTING INSULIN BY GEOGRAPHIC REGION
12.1 Global Short-acting Insulin Market Size Forecast by Region
12.1.1 Global Short-acting Insulin Forecast by Region (2027-2032)
12.1.2 Global Short-acting Insulin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Short-acting Insulin Forecast by Type (2027-2032)
12.7 Global Short-acting Insulin Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Short-acting Insulin Product Portfolios and Specifications
13.1.3 Eli Lilly Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 Novo Nordisk
13.2.1 Novo Nordisk Company Information
13.2.2 Novo Nordisk Short-acting Insulin Product Portfolios and Specifications
13.2.3 Novo Nordisk Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novo Nordisk Main Business Overview
13.2.5 Novo Nordisk Latest Developments
13.3 Biocon Biologics
13.3.1 Biocon Biologics Company Information
13.3.2 Biocon Biologics Short-acting Insulin Product Portfolios and Specifications
13.3.3 Biocon Biologics Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Biocon Biologics Main Business Overview
13.3.5 Biocon Biologics Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Short-acting Insulin Product Portfolios and Specifications
13.4.3 Sanofi Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Wockhardt
13.5.1 Wockhardt Company Information
13.5.2 Wockhardt Short-acting Insulin Product Portfolios and Specifications
13.5.3 Wockhardt Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Wockhardt Main Business Overview
13.5.5 Wockhardt Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Short-acting Insulin Product Portfolios and Specifications
13.6.3 Bayer Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Short-acting Insulin Product Portfolios and Specifications
13.7.3 Pfizer Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 BASF
13.8.1 BASF Company Information
13.8.2 BASF Short-acting Insulin Product Portfolios and Specifications
13.8.3 BASF Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 BASF Main Business Overview
13.8.5 BASF Latest Developments
13.9 Abbott Laboratories
13.9.1 Abbott Laboratories Company Information
13.9.2 Abbott Laboratories Short-acting Insulin Product Portfolios and Specifications
13.9.3 Abbott Laboratories Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Abbott Laboratories Main Business Overview
13.9.5 Abbott Laboratories Latest Developments
13.10 Tonghua Dongbao Pharmaceutical
13.10.1 Tonghua Dongbao Pharmaceutical Company Information
13.10.2 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
13.10.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.11 Zhuhai United Pharmaceutical
13.11.1 Zhuhai United Pharmaceutical Company Information
13.11.2 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
13.11.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Zhuhai United Pharmaceutical Main Business Overview
13.11.5 Zhuhai United Pharmaceutical Latest Developments
13.12 Sinovac Biotech
13.12.1 Sinovac Biotech Company Information
13.12.2 Sinovac Biotech Short-acting Insulin Product Portfolios and Specifications
13.12.3 Sinovac Biotech Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sinovac Biotech Main Business Overview
13.12.5 Sinovac Biotech Latest Developments
13.13 Wanbang Biopharmaceuticals
13.13.1 Wanbang Biopharmaceuticals Company Information
13.13.2 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolios and Specifications
13.13.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Wanbang Biopharmaceuticals Main Business Overview
13.13.5 Wanbang Biopharmaceuticals Latest Developments
13.14 HTBT
13.14.1 HTBT Company Information
13.14.2 HTBT Short-acting Insulin Product Portfolios and Specifications
13.14.3 HTBT Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 HTBT Main Business Overview
13.14.5 HTBT Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Short-acting Insulin Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Short-acting Insulin by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Short-acting Insulin by Country/Region, 2021, 2025 & 2032
2.2 Short-acting Insulin Segment by Type
2.2.1 Regular Insulin
2.2.2 Biosynthetic Human Insulin
2.2.3 Recombinant Human Insulin
2.2.4 Other
2.2.5 Short-acting Insulin Sales by Type
2.2.5.1 Global Short-acting Insulin Sales Market Share by Type (2021-2026)
2.2.5.2 Global Short-acting Insulin Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Short-acting Insulin Sale Price by Type (2021-2026)
2.3 Short-acting Insulin Segment by Application
2.3.1 Type 1 Diabetes
2.3.2 Type 2 Diabetes
2.3.3 Gestational Diabetes
2.3.4 Complications of Diabetes
2.3.5 Other
2.3.6 Short-acting Insulin Sales by Application
2.3.6.1 Global Short-acting Insulin Sale Market Share by Application (2021-2026)
2.3.6.2 Global Short-acting Insulin Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Short-acting Insulin Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Short-acting Insulin Breakdown Data by Company
3.1.1 Global Short-acting Insulin Annual Sales by Company (2021-2026)
3.1.2 Global Short-acting Insulin Sales Market Share by Company (2021-2026)
3.2 Global Short-acting Insulin Annual Revenue by Company (2021-2026)
3.2.1 Global Short-acting Insulin Revenue by Company (2021-2026)
3.2.2 Global Short-acting Insulin Revenue Market Share by Company (2021-2026)
3.3 Global Short-acting Insulin Sale Price by Company
3.4 Key Manufacturers Short-acting Insulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Short-acting Insulin Product Location Distribution
3.4.2 Players Short-acting Insulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SHORT-ACTING INSULIN BY GEOGRAPHIC REGION
4.1 World Historic Short-acting Insulin Market Size by Geographic Region (2021-2026)
4.1.1 Global Short-acting Insulin Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Short-acting Insulin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Short-acting Insulin Market Size by Country/Region (2021-2026)
4.2.1 Global Short-acting Insulin Annual Sales by Country/Region (2021-2026)
4.2.2 Global Short-acting Insulin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Short-acting Insulin Sales Growth
4.4 APAC Short-acting Insulin Sales Growth
4.5 Europe Short-acting Insulin Sales Growth
4.6 Middle East & Africa Short-acting Insulin Sales Growth
5 AMERICAS
5.1 Americas Short-acting Insulin Sales by Country
5.1.1 Americas Short-acting Insulin Sales by Country (2021-2026)
5.1.2 Americas Short-acting Insulin Revenue by Country (2021-2026)
5.2 Americas Short-acting Insulin Sales by Type (2021-2026)
5.3 Americas Short-acting Insulin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Short-acting Insulin Sales by Region
6.1.1 APAC Short-acting Insulin Sales by Region (2021-2026)
6.1.2 APAC Short-acting Insulin Revenue by Region (2021-2026)
6.2 APAC Short-acting Insulin Sales by Type (2021-2026)
6.3 APAC Short-acting Insulin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Short-acting Insulin by Country
7.1.1 Europe Short-acting Insulin Sales by Country (2021-2026)
7.1.2 Europe Short-acting Insulin Revenue by Country (2021-2026)
7.2 Europe Short-acting Insulin Sales by Type (2021-2026)
7.3 Europe Short-acting Insulin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Short-acting Insulin by Country
8.1.1 Middle East & Africa Short-acting Insulin Sales by Country (2021-2026)
8.1.2 Middle East & Africa Short-acting Insulin Revenue by Country (2021-2026)
8.2 Middle East & Africa Short-acting Insulin Sales by Type (2021-2026)
8.3 Middle East & Africa Short-acting Insulin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Short-acting Insulin
10.3 Manufacturing Process Analysis of Short-acting Insulin
10.4 Industry Chain Structure of Short-acting Insulin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Short-acting Insulin Distributors
11.3 Short-acting Insulin Customer
12 WORLD FORECAST REVIEW FOR SHORT-ACTING INSULIN BY GEOGRAPHIC REGION
12.1 Global Short-acting Insulin Market Size Forecast by Region
12.1.1 Global Short-acting Insulin Forecast by Region (2027-2032)
12.1.2 Global Short-acting Insulin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Short-acting Insulin Forecast by Type (2027-2032)
12.7 Global Short-acting Insulin Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Short-acting Insulin Product Portfolios and Specifications
13.1.3 Eli Lilly Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 Novo Nordisk
13.2.1 Novo Nordisk Company Information
13.2.2 Novo Nordisk Short-acting Insulin Product Portfolios and Specifications
13.2.3 Novo Nordisk Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novo Nordisk Main Business Overview
13.2.5 Novo Nordisk Latest Developments
13.3 Biocon Biologics
13.3.1 Biocon Biologics Company Information
13.3.2 Biocon Biologics Short-acting Insulin Product Portfolios and Specifications
13.3.3 Biocon Biologics Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Biocon Biologics Main Business Overview
13.3.5 Biocon Biologics Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Short-acting Insulin Product Portfolios and Specifications
13.4.3 Sanofi Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Wockhardt
13.5.1 Wockhardt Company Information
13.5.2 Wockhardt Short-acting Insulin Product Portfolios and Specifications
13.5.3 Wockhardt Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Wockhardt Main Business Overview
13.5.5 Wockhardt Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Short-acting Insulin Product Portfolios and Specifications
13.6.3 Bayer Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Short-acting Insulin Product Portfolios and Specifications
13.7.3 Pfizer Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 BASF
13.8.1 BASF Company Information
13.8.2 BASF Short-acting Insulin Product Portfolios and Specifications
13.8.3 BASF Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 BASF Main Business Overview
13.8.5 BASF Latest Developments
13.9 Abbott Laboratories
13.9.1 Abbott Laboratories Company Information
13.9.2 Abbott Laboratories Short-acting Insulin Product Portfolios and Specifications
13.9.3 Abbott Laboratories Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Abbott Laboratories Main Business Overview
13.9.5 Abbott Laboratories Latest Developments
13.10 Tonghua Dongbao Pharmaceutical
13.10.1 Tonghua Dongbao Pharmaceutical Company Information
13.10.2 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
13.10.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.11 Zhuhai United Pharmaceutical
13.11.1 Zhuhai United Pharmaceutical Company Information
13.11.2 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
13.11.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Zhuhai United Pharmaceutical Main Business Overview
13.11.5 Zhuhai United Pharmaceutical Latest Developments
13.12 Sinovac Biotech
13.12.1 Sinovac Biotech Company Information
13.12.2 Sinovac Biotech Short-acting Insulin Product Portfolios and Specifications
13.12.3 Sinovac Biotech Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sinovac Biotech Main Business Overview
13.12.5 Sinovac Biotech Latest Developments
13.13 Wanbang Biopharmaceuticals
13.13.1 Wanbang Biopharmaceuticals Company Information
13.13.2 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolios and Specifications
13.13.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Wanbang Biopharmaceuticals Main Business Overview
13.13.5 Wanbang Biopharmaceuticals Latest Developments
13.14 HTBT
13.14.1 HTBT Company Information
13.14.2 HTBT Short-acting Insulin Product Portfolios and Specifications
13.14.3 HTBT Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 HTBT Main Business Overview
13.14.5 HTBT Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Short-acting Insulin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Short-acting Insulin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Regular Insulin
Table 4. Major Players of Biosynthetic Human Insulin
Table 5. Major Players of Recombinant Human Insulin
Table 6. Major Players of Other
Table 7. Global Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 8. Global Short-acting Insulin Sales Market Share by Type (2021-2026)
Table 9. Global Short-acting Insulin Revenue by Type (2021-2026) & ($ million)
Table 10. Global Short-acting Insulin Revenue Market Share by Type (2021-2026)
Table 11. Global Short-acting Insulin Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Short-acting Insulin Sale by Application (2021-2026) & (K Units)
Table 13. Global Short-acting Insulin Sale Market Share by Application (2021-2026)
Table 14. Global Short-acting Insulin Revenue by Application (2021-2026) & ($ million)
Table 15. Global Short-acting Insulin Revenue Market Share by Application (2021-2026)
Table 16. Global Short-acting Insulin Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Short-acting Insulin Sales by Company (2021-2026) & (K Units)
Table 18. Global Short-acting Insulin Sales Market Share by Company (2021-2026)
Table 19. Global Short-acting Insulin Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Short-acting Insulin Revenue Market Share by Company (2021-2026)
Table 21. Global Short-acting Insulin Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Short-acting Insulin Producing Area Distribution and Sales Area
Table 23. Players Short-acting Insulin Products Offered
Table 24. Short-acting Insulin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Short-acting Insulin Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Short-acting Insulin Sales Market Share Geographic Region (2021-2026)
Table 29. Global Short-acting Insulin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Short-acting Insulin Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Short-acting Insulin Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Short-acting Insulin Sales Market Share by Country/Region (2021-2026)
Table 33. Global Short-acting Insulin Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Short-acting Insulin Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Short-acting Insulin Sales by Country (2021-2026) & (K Units)
Table 36. Americas Short-acting Insulin Sales Market Share by Country (2021-2026)
Table 37. Americas Short-acting Insulin Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 39. Americas Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 40. APAC Short-acting Insulin Sales by Region (2021-2026) & (K Units)
Table 41. APAC Short-acting Insulin Sales Market Share by Region (2021-2026)
Table 42. APAC Short-acting Insulin Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 44. APAC Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 45. Europe Short-acting Insulin Sales by Country (2021-2026) & (K Units)
Table 46. Europe Short-acting Insulin Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 48. Europe Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Short-acting Insulin Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Short-acting Insulin Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Short-acting Insulin
Table 54. Key Market Challenges & Risks of Short-acting Insulin
Table 55. Key Industry Trends of Short-acting Insulin
Table 56. Short-acting Insulin Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Short-acting Insulin Distributors List
Table 59. Short-acting Insulin Customer List
Table 60. Global Short-acting Insulin Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Short-acting Insulin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Short-acting Insulin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Short-acting Insulin Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Short-acting Insulin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Short-acting Insulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Short-acting Insulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Short-acting Insulin Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Short-acting Insulin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Short-acting Insulin Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Short-acting Insulin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Eli Lilly Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 75. Eli Lilly Short-acting Insulin Product Portfolios and Specifications
Table 76. Eli Lilly Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Eli Lilly Main Business
Table 78. Eli Lilly Latest Developments
Table 79. Novo Nordisk Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 80. Novo Nordisk Short-acting Insulin Product Portfolios and Specifications
Table 81. Novo Nordisk Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Novo Nordisk Main Business
Table 83. Novo Nordisk Latest Developments
Table 84. Biocon Biologics Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 85. Biocon Biologics Short-acting Insulin Product Portfolios and Specifications
Table 86. Biocon Biologics Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Biocon Biologics Main Business
Table 88. Biocon Biologics Latest Developments
Table 89. Sanofi Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi Short-acting Insulin Product Portfolios and Specifications
Table 91. Sanofi Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Wockhardt Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 95. Wockhardt Short-acting Insulin Product Portfolios and Specifications
Table 96. Wockhardt Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Wockhardt Main Business
Table 98. Wockhardt Latest Developments
Table 99. Bayer Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 100. Bayer Short-acting Insulin Product Portfolios and Specifications
Table 101. Bayer Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Bayer Main Business
Table 103. Bayer Latest Developments
Table 104. Pfizer Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 105. Pfizer Short-acting Insulin Product Portfolios and Specifications
Table 106. Pfizer Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Pfizer Main Business
Table 108. Pfizer Latest Developments
Table 109. BASF Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 110. BASF Short-acting Insulin Product Portfolios and Specifications
Table 111. BASF Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. BASF Main Business
Table 113. BASF Latest Developments
Table 114. Abbott Laboratories Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 115. Abbott Laboratories Short-acting Insulin Product Portfolios and Specifications
Table 116. Abbott Laboratories Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Abbott Laboratories Main Business
Table 118. Abbott Laboratories Latest Developments
Table 119. Tonghua Dongbao Pharmaceutical Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 120. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
Table 121. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Tonghua Dongbao Pharmaceutical Main Business
Table 123. Tonghua Dongbao Pharmaceutical Latest Developments
Table 124. Zhuhai United Pharmaceutical Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 125. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
Table 126. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Zhuhai United Pharmaceutical Main Business
Table 128. Zhuhai United Pharmaceutical Latest Developments
Table 129. Sinovac Biotech Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 130. Sinovac Biotech Short-acting Insulin Product Portfolios and Specifications
Table 131. Sinovac Biotech Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Sinovac Biotech Main Business
Table 133. Sinovac Biotech Latest Developments
Table 134. Wanbang Biopharmaceuticals Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 135. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolios and Specifications
Table 136. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Wanbang Biopharmaceuticals Main Business
Table 138. Wanbang Biopharmaceuticals Latest Developments
Table 139. HTBT Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 140. HTBT Short-acting Insulin Product Portfolios and Specifications
Table 141. HTBT Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. HTBT Main Business
Table 143. HTBT Latest Developments
Table 1. Short-acting Insulin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Short-acting Insulin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Regular Insulin
Table 4. Major Players of Biosynthetic Human Insulin
Table 5. Major Players of Recombinant Human Insulin
Table 6. Major Players of Other
Table 7. Global Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 8. Global Short-acting Insulin Sales Market Share by Type (2021-2026)
Table 9. Global Short-acting Insulin Revenue by Type (2021-2026) & ($ million)
Table 10. Global Short-acting Insulin Revenue Market Share by Type (2021-2026)
Table 11. Global Short-acting Insulin Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Short-acting Insulin Sale by Application (2021-2026) & (K Units)
Table 13. Global Short-acting Insulin Sale Market Share by Application (2021-2026)
Table 14. Global Short-acting Insulin Revenue by Application (2021-2026) & ($ million)
Table 15. Global Short-acting Insulin Revenue Market Share by Application (2021-2026)
Table 16. Global Short-acting Insulin Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Short-acting Insulin Sales by Company (2021-2026) & (K Units)
Table 18. Global Short-acting Insulin Sales Market Share by Company (2021-2026)
Table 19. Global Short-acting Insulin Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Short-acting Insulin Revenue Market Share by Company (2021-2026)
Table 21. Global Short-acting Insulin Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Short-acting Insulin Producing Area Distribution and Sales Area
Table 23. Players Short-acting Insulin Products Offered
Table 24. Short-acting Insulin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Short-acting Insulin Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Short-acting Insulin Sales Market Share Geographic Region (2021-2026)
Table 29. Global Short-acting Insulin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Short-acting Insulin Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Short-acting Insulin Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Short-acting Insulin Sales Market Share by Country/Region (2021-2026)
Table 33. Global Short-acting Insulin Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Short-acting Insulin Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Short-acting Insulin Sales by Country (2021-2026) & (K Units)
Table 36. Americas Short-acting Insulin Sales Market Share by Country (2021-2026)
Table 37. Americas Short-acting Insulin Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 39. Americas Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 40. APAC Short-acting Insulin Sales by Region (2021-2026) & (K Units)
Table 41. APAC Short-acting Insulin Sales Market Share by Region (2021-2026)
Table 42. APAC Short-acting Insulin Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 44. APAC Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 45. Europe Short-acting Insulin Sales by Country (2021-2026) & (K Units)
Table 46. Europe Short-acting Insulin Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 48. Europe Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Short-acting Insulin Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Short-acting Insulin Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Short-acting Insulin Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Short-acting Insulin Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Short-acting Insulin
Table 54. Key Market Challenges & Risks of Short-acting Insulin
Table 55. Key Industry Trends of Short-acting Insulin
Table 56. Short-acting Insulin Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Short-acting Insulin Distributors List
Table 59. Short-acting Insulin Customer List
Table 60. Global Short-acting Insulin Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Short-acting Insulin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Short-acting Insulin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Short-acting Insulin Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Short-acting Insulin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Short-acting Insulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Short-acting Insulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Short-acting Insulin Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Short-acting Insulin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Short-acting Insulin Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Short-acting Insulin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Eli Lilly Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 75. Eli Lilly Short-acting Insulin Product Portfolios and Specifications
Table 76. Eli Lilly Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Eli Lilly Main Business
Table 78. Eli Lilly Latest Developments
Table 79. Novo Nordisk Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 80. Novo Nordisk Short-acting Insulin Product Portfolios and Specifications
Table 81. Novo Nordisk Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Novo Nordisk Main Business
Table 83. Novo Nordisk Latest Developments
Table 84. Biocon Biologics Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 85. Biocon Biologics Short-acting Insulin Product Portfolios and Specifications
Table 86. Biocon Biologics Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Biocon Biologics Main Business
Table 88. Biocon Biologics Latest Developments
Table 89. Sanofi Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi Short-acting Insulin Product Portfolios and Specifications
Table 91. Sanofi Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Wockhardt Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 95. Wockhardt Short-acting Insulin Product Portfolios and Specifications
Table 96. Wockhardt Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Wockhardt Main Business
Table 98. Wockhardt Latest Developments
Table 99. Bayer Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 100. Bayer Short-acting Insulin Product Portfolios and Specifications
Table 101. Bayer Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Bayer Main Business
Table 103. Bayer Latest Developments
Table 104. Pfizer Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 105. Pfizer Short-acting Insulin Product Portfolios and Specifications
Table 106. Pfizer Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Pfizer Main Business
Table 108. Pfizer Latest Developments
Table 109. BASF Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 110. BASF Short-acting Insulin Product Portfolios and Specifications
Table 111. BASF Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. BASF Main Business
Table 113. BASF Latest Developments
Table 114. Abbott Laboratories Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 115. Abbott Laboratories Short-acting Insulin Product Portfolios and Specifications
Table 116. Abbott Laboratories Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Abbott Laboratories Main Business
Table 118. Abbott Laboratories Latest Developments
Table 119. Tonghua Dongbao Pharmaceutical Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 120. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
Table 121. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Tonghua Dongbao Pharmaceutical Main Business
Table 123. Tonghua Dongbao Pharmaceutical Latest Developments
Table 124. Zhuhai United Pharmaceutical Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 125. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolios and Specifications
Table 126. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Zhuhai United Pharmaceutical Main Business
Table 128. Zhuhai United Pharmaceutical Latest Developments
Table 129. Sinovac Biotech Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 130. Sinovac Biotech Short-acting Insulin Product Portfolios and Specifications
Table 131. Sinovac Biotech Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Sinovac Biotech Main Business
Table 133. Sinovac Biotech Latest Developments
Table 134. Wanbang Biopharmaceuticals Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 135. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolios and Specifications
Table 136. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Wanbang Biopharmaceuticals Main Business
Table 138. Wanbang Biopharmaceuticals Latest Developments
Table 139. HTBT Basic Information, Short-acting Insulin Manufacturing Base, Sales Area and Its Competitors
Table 140. HTBT Short-acting Insulin Product Portfolios and Specifications
Table 141. HTBT Short-acting Insulin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. HTBT Main Business
Table 143. HTBT Latest Developments
LIST OF FIGURES
Figure 1. Picture of Short-acting Insulin
Figure 2. Short-acting Insulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Short-acting Insulin Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Short-acting Insulin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Short-acting Insulin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Short-acting Insulin Sales Market Share by Country/Region (2025)
Figure 10. Short-acting Insulin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Regular Insulin
Figure 12. Product Picture of Biosynthetic Human Insulin
Figure 13. Product Picture of Recombinant Human Insulin
Figure 14. Product Picture of Other
Figure 15. Global Short-acting Insulin Sales Market Share by Type in 2026
Figure 16. Global Short-acting Insulin Revenue Market Share by Type (2021-2026)
Figure 17. Short-acting Insulin Consumed in Type 1 Diabetes
Figure 18. Global Short-acting Insulin Market: Type 1 Diabetes (2021-2026) & (K Units)
Figure 19. Short-acting Insulin Consumed in Type 2 Diabetes
Figure 20. Global Short-acting Insulin Market: Type 2 Diabetes (2021-2026) & (K Units)
Figure 21. Short-acting Insulin Consumed in Gestational Diabetes
Figure 22. Global Short-acting Insulin Market: Gestational Diabetes (2021-2026) & (K Units)
Figure 23. Short-acting Insulin Consumed in Complications of Diabetes
Figure 24. Global Short-acting Insulin Market: Complications of Diabetes (2021-2026) & (K Units)
Figure 25. Short-acting Insulin Consumed in Other
Figure 26. Global Short-acting Insulin Market: Other (2021-2026) & (K Units)
Figure 27. Global Short-acting Insulin Sale Market Share by Application (2025)
Figure 28. Global Short-acting Insulin Revenue Market Share by Application in 2026
Figure 29. Short-acting Insulin Sales by Company in 2026 (K Units)
Figure 30. Global Short-acting Insulin Sales Market Share by Company in 2026
Figure 31. Short-acting Insulin Revenue by Company in 2026 ($ millions)
Figure 32. Global Short-acting Insulin Revenue Market Share by Company in 2026
Figure 33. Global Short-acting Insulin Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global Short-acting Insulin Revenue Market Share by Geographic Region in 2026
Figure 35. Americas Short-acting Insulin Sales 2021-2026 (K Units)
Figure 36. Americas Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 37. APAC Short-acting Insulin Sales 2021-2026 (K Units)
Figure 38. APAC Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 39. Europe Short-acting Insulin Sales 2021-2026 (K Units)
Figure 40. Europe Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa Short-acting Insulin Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 43. Americas Short-acting Insulin Sales Market Share by Country in 2026
Figure 44. Americas Short-acting Insulin Revenue Market Share by Country (2021-2026)
Figure 45. Americas Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 46. Americas Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 47. United States Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC Short-acting Insulin Sales Market Share by Region in 2026
Figure 52. APAC Short-acting Insulin Revenue Market Share by Region (2021-2026)
Figure 53. APAC Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 54. APAC Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 55. China Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 59. India Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe Short-acting Insulin Sales Market Share by Country in 2026
Figure 63. Europe Short-acting Insulin Revenue Market Share by Country (2021-2026)
Figure 64. Europe Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 65. Europe Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 66. Germany Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 67. France Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 68. UK Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa Short-acting Insulin Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 74. Egypt Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Short-acting Insulin in 2026
Figure 80. Manufacturing Process Analysis of Short-acting Insulin
Figure 81. Industry Chain Structure of Short-acting Insulin
Figure 82. Channels of Distribution
Figure 83. Global Short-acting Insulin Sales Market Forecast by Region (2027-2032)
Figure 84. Global Short-acting Insulin Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global Short-acting Insulin Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global Short-acting Insulin Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global Short-acting Insulin Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global Short-acting Insulin Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Short-acting Insulin
Figure 2. Short-acting Insulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Short-acting Insulin Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Short-acting Insulin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Short-acting Insulin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Short-acting Insulin Sales Market Share by Country/Region (2025)
Figure 10. Short-acting Insulin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Regular Insulin
Figure 12. Product Picture of Biosynthetic Human Insulin
Figure 13. Product Picture of Recombinant Human Insulin
Figure 14. Product Picture of Other
Figure 15. Global Short-acting Insulin Sales Market Share by Type in 2026
Figure 16. Global Short-acting Insulin Revenue Market Share by Type (2021-2026)
Figure 17. Short-acting Insulin Consumed in Type 1 Diabetes
Figure 18. Global Short-acting Insulin Market: Type 1 Diabetes (2021-2026) & (K Units)
Figure 19. Short-acting Insulin Consumed in Type 2 Diabetes
Figure 20. Global Short-acting Insulin Market: Type 2 Diabetes (2021-2026) & (K Units)
Figure 21. Short-acting Insulin Consumed in Gestational Diabetes
Figure 22. Global Short-acting Insulin Market: Gestational Diabetes (2021-2026) & (K Units)
Figure 23. Short-acting Insulin Consumed in Complications of Diabetes
Figure 24. Global Short-acting Insulin Market: Complications of Diabetes (2021-2026) & (K Units)
Figure 25. Short-acting Insulin Consumed in Other
Figure 26. Global Short-acting Insulin Market: Other (2021-2026) & (K Units)
Figure 27. Global Short-acting Insulin Sale Market Share by Application (2025)
Figure 28. Global Short-acting Insulin Revenue Market Share by Application in 2026
Figure 29. Short-acting Insulin Sales by Company in 2026 (K Units)
Figure 30. Global Short-acting Insulin Sales Market Share by Company in 2026
Figure 31. Short-acting Insulin Revenue by Company in 2026 ($ millions)
Figure 32. Global Short-acting Insulin Revenue Market Share by Company in 2026
Figure 33. Global Short-acting Insulin Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global Short-acting Insulin Revenue Market Share by Geographic Region in 2026
Figure 35. Americas Short-acting Insulin Sales 2021-2026 (K Units)
Figure 36. Americas Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 37. APAC Short-acting Insulin Sales 2021-2026 (K Units)
Figure 38. APAC Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 39. Europe Short-acting Insulin Sales 2021-2026 (K Units)
Figure 40. Europe Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa Short-acting Insulin Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa Short-acting Insulin Revenue 2021-2026 ($ millions)
Figure 43. Americas Short-acting Insulin Sales Market Share by Country in 2026
Figure 44. Americas Short-acting Insulin Revenue Market Share by Country (2021-2026)
Figure 45. Americas Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 46. Americas Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 47. United States Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC Short-acting Insulin Sales Market Share by Region in 2026
Figure 52. APAC Short-acting Insulin Revenue Market Share by Region (2021-2026)
Figure 53. APAC Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 54. APAC Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 55. China Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 59. India Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe Short-acting Insulin Sales Market Share by Country in 2026
Figure 63. Europe Short-acting Insulin Revenue Market Share by Country (2021-2026)
Figure 64. Europe Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 65. Europe Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 66. Germany Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 67. France Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 68. UK Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa Short-acting Insulin Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa Short-acting Insulin Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa Short-acting Insulin Sales Market Share by Application (2021-2026)
Figure 74. Egypt Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries Short-acting Insulin Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Short-acting Insulin in 2026
Figure 80. Manufacturing Process Analysis of Short-acting Insulin
Figure 81. Industry Chain Structure of Short-acting Insulin
Figure 82. Channels of Distribution
Figure 83. Global Short-acting Insulin Sales Market Forecast by Region (2027-2032)
Figure 84. Global Short-acting Insulin Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global Short-acting Insulin Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global Short-acting Insulin Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global Short-acting Insulin Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global Short-acting Insulin Revenue Market Share Forecast by Application (2027-2032)
